- Home
- YMAB vs RERE Comparison
YMAB vs RERE Comparison
Compare YMAB & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- RERE
- Stock Information
- Founded
- YMAB 2015
- RERE 2011
- Country
- YMAB United States
- RERE China
- Employees
- YMAB N/A
- RERE N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- YMAB Health Care
- RERE Consumer Discretionary
- Exchange
- YMAB Nasdaq
- RERE Nasdaq
- Market Cap
- YMAB 482.4M
- RERE 527.7M
- IPO Year
- YMAB 2018
- RERE 2021
- Fundamental
- Price
- YMAB $9.38
- RERE $2.92
- Analyst Decision
- YMAB Strong Buy
- RERE
- Analyst Count
- YMAB 10
- RERE 0
- Target Price
- YMAB $21.00
- RERE N/A
- AVG Volume (30 Days)
- YMAB 243.1K
- RERE 1.9M
- Earning Date
- YMAB 11-08-2024
- RERE 11-20-2024
- Dividend Yield
- YMAB N/A
- RERE N/A
- EPS Growth
- YMAB N/A
- RERE N/A
- EPS
- YMAB N/A
- RERE N/A
- Revenue
- YMAB $84,553,000.00
- RERE $2,188,701,829.00
- Revenue This Year
- YMAB $6.46
- RERE $28.08
- Revenue Next Year
- YMAB $20.68
- RERE $25.05
- P/E Ratio
- YMAB N/A
- RERE N/A
- Revenue Growth
- YMAB N/A
- RERE 27.16
- 52 Week Low
- YMAB $6.09
- RERE $1.01
- 52 Week High
- YMAB $20.90
- RERE $3.70
- Technical
- Relative Strength Index (RSI)
- YMAB 32.17
- RERE 50.85
- Support Level
- YMAB $9.31
- RERE $2.92
- Resistance Level
- YMAB $11.10
- RERE $3.15
- Average True Range (ATR)
- YMAB 0.72
- RERE 0.20
- MACD
- YMAB -0.00
- RERE -0.05
- Stochastic Oscillator
- YMAB 3.87
- RERE 20.22
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.